PGE selects ADVA’s assured PNT solution for critical smart grid infrastructure
18.8.2021 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Portland General Electric (PGE) is deploying Oscilloquartz PTP grandmaster clock technology as it upgrades to packet-based synchronization and protects its network against GNSS vulnerabilities and cyberattacks, while conforming to PNT Executive Order 13905. PGE, one of the largest power utilities in the Western United States, is using ADVA scalable timing solution to not only enable a smooth transition from legacy synchronization and ensure new levels of accuracy, reliability and resiliency but also to timestamp data and control grid substations at the edge. With multi-band GNSS receivers and AI-powered threat detection, ADVA’s assured PNT (aPNT) platform helps maintain resilient timing, even in challenging circumstances such as deliberate jamming and spoofing attacks. Easy to install and operate, the solution also provides multi-source backup, including PTP network timing and in-device holdover oscillators for when GNSS signals are unavailable or disrupted.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210818005033/en/
ADVA’s aPNT platform is key for the development of PGE’s critical network infrastructure (Photo: Business Wire)
“Precise and resilient synchronization is increasingly vital in the power industry. By harnessing new time-sensitive applications and building smarter energy infrastructure, we can offer even more to customers across our region. ADVA’s Oscilloquartz technology will be a key tool as we continue to lead the way to a more sustainable and affordable energy future for our community,” said John Lozano, senior telecommunications engineer, PGE. “ADVA’s OSA 5420 Series supports our existing synchronization services while also enabling packet time distribution all the way to the edge of our network. With its GPS jamming and spoofing detection, it provides a robust yet cost-efficient defense against cyber threats. It also makes maintenance and configuration simple with an easy-to-operate web GUI and customizable database.”
PGE’s new timing infrastructure will distribute stable and accurate frequency, phase and time-of-day information between its power infrastructure data points, including PMUs, IEDs and substation LAN IEC 61850 communications, supporting rapid decision-making and automated assurance. The solution is built on the OSA 5410 and OSA 5420 Series of edgeSync+™ grandmaster clocks. It features multi-band, multi-constellation GNSS receivers and supports multiple PTP profiles, including substation power and core telecom backup sync, while also allowing conversion between them and supporting legacy interfaces. The products are part of ADVA’s new aPNT platform, integrating threat detection, multi-source backup and ADVA’s intelligent Ensemble Sync Director, as the new trusted standard for PNT service assurance, control and visibility.
“We’re proud that PGE is leveraging our synchronization technology and the support of our team as it makes the shift to next-generation timing. With its compact and environmentally friendly design, our technology will bring assured and protected synchronization to the edge of PGE’s network, enhancing efficiency and enabling it to take advantage of emerging smart grid applications,” commented John Scherzinger, SVP, sales, Americas, ADVA. “PGE’s highly resilient new solution will deliver the nanosecond accuracy and the levels of timing availability required by tomorrow’s power utilities. It features aPNT capabilities, our centralized GNSS monitoring and assurance tool for predictive maintenance, and our multi-band receivers with the power to compensate for ionospheric delay variations and protect against GNSS vulnerabilities.”
Further information on ADVA’s aPNT platform is available in this sync guide: https://adva.li/apnt-sync-guide.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005033/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
